Репозиторий OAI—PMH
Репозиторий Российская Офтальмология Онлайн по протоколу OAI-PMH
Конференции
Офтальмологические конференции и симпозиумы
Видео
Видео докладов
Реферат RUS | Реферат ENG | Литература | Полный текст |
УДК: | DOI: https://doi.org/10.25276/2312-4911-2021-3-284-288 |
Аит Ахмед Х., Семенова Т.Н., Соловейчик И.Б., Арсютов Д.Г., Максимов В.Ю.
Исследование эффективности антиангиогенной терапии диабетического макулярного отека на авитреальных глазах в условиях реальной клинической практики
1. Шадричев Ф.Е., Григорьева Н.Н., Рождественская Е.С. Антиангиогенная терапия при диабетическом макулярном отеке / Офтальмологические ведомости. – 2018. – Т. 11. – № 4. – С. 51–66. doi: 10.17816/OV11451-66
2. Bressler SB, Melia M, Glassman AR, et al. Ranibizumab Plus Prompt or Deferred Laser for Diabetic Macular Edema in Eyes with Vitrectomy Prior to Anti-Vascular Endothelial Growth Factor Therapy / Retina. 2015; 35(12): 2516–2528. doi:10.1097/IAE.0000000000000617
3. Bressler NM, Beaulieu WT, Glassman AR, et al. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema with Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2018; 136(3): 257-269. doi: 10.1001/ jamaophthalmol.2017.6565
4. Jampol LM, Glassman AR, Bressler NM, et al. Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial. JAMA Ophthalmol. 2016; 134(12). doi: 10.1001/jamaophthalmol.2016.3698.
5. Nomoto H, Shiraga F, Kuno N et al. Pharmacokinetics of Bevacizumab after Topical, Subconjunctival, and Intravitreal Administration in Rabbits / Invest Ophthalmol Vis Sci. 2009; 50: 4807– 4813) DOI:10.1167/iovs.08-3148
6. Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, et al. Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory. J Diabetes Res. 2016;2016:2156273. doi: 10.1155/ 2016/2156273
7. Totuk OM , Kanra AY, Bromand MN et al. Effectiveness of Intravitreal Ranibizumab in Nonvitrectomized and Vitrectomized Eyes with Diabetic Macular Edema: A Two-Year Retrospective Analysis/Journal of Ophthalmology Volume 2020, Article ID 2561251, 8 pages https:/doi.org/10.1155/2020/2561251
8. Xu Y, You Y, Du W et al. Ocular Pharmacokinetics of Bevacizumab in Vitrectomized Eyes with Silicone Oil Tamponade/Invest Ophthalmol Vis Sci. 2012;53:5221–5226) DOI:10.1167/iovs.12-9702
2. Bressler SB, Melia M, Glassman AR, et al. Ranibizumab Plus Prompt or Deferred Laser for Diabetic Macular Edema in Eyes with Vitrectomy Prior to Anti-Vascular Endothelial Growth Factor Therapy / Retina. 2015; 35(12): 2516–2528. doi:10.1097/IAE.0000000000000617
3. Bressler NM, Beaulieu WT, Glassman AR, et al. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema with Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2018; 136(3): 257-269. doi: 10.1001/ jamaophthalmol.2017.6565
4. Jampol LM, Glassman AR, Bressler NM, et al. Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial. JAMA Ophthalmol. 2016; 134(12). doi: 10.1001/jamaophthalmol.2016.3698.
5. Nomoto H, Shiraga F, Kuno N et al. Pharmacokinetics of Bevacizumab after Topical, Subconjunctival, and Intravitreal Administration in Rabbits / Invest Ophthalmol Vis Sci. 2009; 50: 4807– 4813) DOI:10.1167/iovs.08-3148
6. Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, et al. Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory. J Diabetes Res. 2016;2016:2156273. doi: 10.1155/ 2016/2156273
7. Totuk OM , Kanra AY, Bromand MN et al. Effectiveness of Intravitreal Ranibizumab in Nonvitrectomized and Vitrectomized Eyes with Diabetic Macular Edema: A Two-Year Retrospective Analysis/Journal of Ophthalmology Volume 2020, Article ID 2561251, 8 pages https:/doi.org/10.1155/2020/2561251
8. Xu Y, You Y, Du W et al. Ocular Pharmacokinetics of Bevacizumab in Vitrectomized Eyes with Silicone Oil Tamponade/Invest Ophthalmol Vis Sci. 2012;53:5221–5226) DOI:10.1167/iovs.12-9702
Страница источника: 284-288
Каталог
Продукции
Организации
Офтальмологические клиники, производители и поставщики оборудования
Издания
Периодические издания
Партнеры
Проекта Российская Офтальмология Онлайн